- Published at
- by smallcaps.com.au
neutral
neutral
Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial
Invion (ASX: IVX) has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II